These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28157594)

  • 21. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
    Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):329-32. PubMed ID: 16263233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
    Sader HS; Farrell DJ; Jones RN
    J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of vancomycin-resistant Enterococcus spp. clinical isolates recovered from hospitalized patients among several medical institutions in China.
    Sun H; Wang H; Xu Y; Jones RN; Costello AJ; Liu Y; Li G; Chen M; Mendes RE
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):399-403. PubMed ID: 23099304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.
    Opoku-Temeng C; Naclerio GA; Mohammad H; Dayal N; Abutaleb NS; Seleem MN; Sintim HO
    Eur J Med Chem; 2018 Jul; 155():797-805. PubMed ID: 29957525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India.
    Dhawan B; Gadepalli R; Kapil A
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):196-8. PubMed ID: 19748433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.
    Bush LM; Boscia JA; Wendeler M; Pitsakis PG; Kaye D
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1198-200. PubMed ID: 2552901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
    Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
    Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD; Citron DM
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of vancomycin, linezolid, and daptomycin against staphylococci and enterococci isolated in 5 Greek hospitals during a 5-year period (2008-2012).
    Papadimitriou-Olivgeris M; Kolonitsiou F; Zerva L; Lebessi E; Koutsia C; Drougka E; Sarrou S; Giormezis N; Vourli S; Doudoulakakis A; Konsolakis C; Marangos M; Anastassiou ED; Petinaki E; Spiliopoulou I
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):386-8. PubMed ID: 26341703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
    Cunha BA; Mickail N; Eisenstein L
    Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.
    Laganas V; Alder J; Silverman JA
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2682-4. PubMed ID: 12878541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemiology of the infection by resistant Gram-positive microorganisms].
    Cercenado E
    Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():6-9. PubMed ID: 27608305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.